Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

An investigation of carbapenemase-encoding genes in Burkholderia cepacia and Aeromonas sobria nosocomial infections among Iraqi patients

View through CrossRef
Abstract Burkholderia cepacia and Aeromonas sobria are difficult to eradicate due to their innate resistance to a variety of medications, and cause various diseases. The aim of this study was to investigate the occurrence of carbapenemase genes and patterns of antibiotic resistance in isolates of B. cepacia and A. sobria. A cross-sectional study was conducted in the Ramadi Teaching Hospitals in the Al-Anbar Governorate in 2024. Various study samples, were used to collect the studied bacteria. The antibiotic resistance was detected by the VITEK®2 System. The presence of carbapenemase genes was confirmed via PCR technique. In this investigation, seventy-five (75) isolates of A. sobria and B. cepacia were assessed. Of these, A. sobria made up 16.6% (n = 20) while B. cepacia accounted for 45.8% (n = 55). The study isolates showed highest antimicrobial resistance to piperacillin, cefepime, ceftriaxone (100%), ceftazidime (97.3%), and lowest antimicrobial resistance to imipenem (36%). The result showed 55/57 recA gene positive for differentiated B. cepacia complex from other Burkholderia spp. The overall prevalence of carbapenemase genes was 92.8%% (52/56) with bla KPC accounting for 80.8% (42/52) and bla GES for 19.2% (10/52) of the total. The 42 B. cepacia isolates that tested positive for carbapenem resistance were constituted of 38 bla KPC (n = 38) and two bla GES (n = 2); in contrast, four bla KPC (n = 4) and eight bla GES (n = 8) were present in the A. sobria isolates that tested positive for carbapenems resistance. None of isolates studied tested positive for the bla IMP gene. The recent study concluded that recA gene identification was more sensitive and specific technique for detection B. cepacia complex isolates. There was a notable predominance of bla KPC and bla GES carbapenemase producers among the isolates under investigation. The bla IMP gene was not found in any of the research isolates.
Title: An investigation of carbapenemase-encoding genes in Burkholderia cepacia and Aeromonas sobria nosocomial infections among Iraqi patients
Description:
Abstract Burkholderia cepacia and Aeromonas sobria are difficult to eradicate due to their innate resistance to a variety of medications, and cause various diseases.
The aim of this study was to investigate the occurrence of carbapenemase genes and patterns of antibiotic resistance in isolates of B.
cepacia and A.
sobria.
A cross-sectional study was conducted in the Ramadi Teaching Hospitals in the Al-Anbar Governorate in 2024.
Various study samples, were used to collect the studied bacteria.
The antibiotic resistance was detected by the VITEK®2 System.
The presence of carbapenemase genes was confirmed via PCR technique.
In this investigation, seventy-five (75) isolates of A.
sobria and B.
cepacia were assessed.
Of these, A.
sobria made up 16.
6% (n = 20) while B.
cepacia accounted for 45.
8% (n = 55).
The study isolates showed highest antimicrobial resistance to piperacillin, cefepime, ceftriaxone (100%), ceftazidime (97.
3%), and lowest antimicrobial resistance to imipenem (36%).
The result showed 55/57 recA gene positive for differentiated B.
cepacia complex from other Burkholderia spp.
The overall prevalence of carbapenemase genes was 92.
8%% (52/56) with bla KPC accounting for 80.
8% (42/52) and bla GES for 19.
2% (10/52) of the total.
The 42 B.
cepacia isolates that tested positive for carbapenem resistance were constituted of 38 bla KPC (n = 38) and two bla GES (n = 2); in contrast, four bla KPC (n = 4) and eight bla GES (n = 8) were present in the A.
sobria isolates that tested positive for carbapenems resistance.
None of isolates studied tested positive for the bla IMP gene.
The recent study concluded that recA gene identification was more sensitive and specific technique for detection B.
cepacia complex isolates.
There was a notable predominance of bla KPC and bla GES carbapenemase producers among the isolates under investigation.
The bla IMP gene was not found in any of the research isolates.

Related Results

Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract Introduction Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
ANTIBIOTIC PROFILE OF BURKHOLDERIA CEPACIA IN TERTIARY CARE HOSPITAL, VADODARA, GUJARAT, INDIA.
ANTIBIOTIC PROFILE OF BURKHOLDERIA CEPACIA IN TERTIARY CARE HOSPITAL, VADODARA, GUJARAT, INDIA.
Since the early 1980's, Burkholderia cepacia is emerged as a causative agent of opportunistic human infections. Burkholderia cepacia (B. cepacia) is an opportunistic pathogen which...
Aeromonas sobria as a potential candidate for bioremediation of heavy metal from contaminated environments
Aeromonas sobria as a potential candidate for bioremediation of heavy metal from contaminated environments
AbstractThe uncontrolled discharge of industrial wastes causes the accumulation of high heavy metal concentrations in soil and water, leading to many health issues. In the present ...
Phenotypic characterization of carbapenem non-susceptible gram-negative bacilli isolated from clinical specimens
Phenotypic characterization of carbapenem non-susceptible gram-negative bacilli isolated from clinical specimens
Background Multidrug resistant, extremely drug-resistant, pan-drug resistant, carbapenem-resistant, and carbapenemase-producing gram-negative bacteria are becoming more common in h...
Isolation and characterization of bacteriophages against Burkholderia species
Isolation and characterization of bacteriophages against Burkholderia species
Abstract Burkholderia cepacia complex (Bcc) is a potent nosocomial pathogen mainly encountered in immunocompromised, cystic fibrosis and chronic granulomatous patients. The...

Back to Top